Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative

Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation of diabetes. At the time of writing, metformin as an...

Full description

Bibliographic Details
Main Authors:	Prabhakaran, Sonia, Thirumal , Dhiviya, Jolius, Gimbun, Ranganathan, Balu
Format:	Article
Language:	English
Published:	Informatics Publishing Limited 2017
Subjects:	TP Chemical technology
Online Access:	http://umpir.ump.edu.my/id/eprint/20659/ http://umpir.ump.edu.my/id/eprint/20659/ http://umpir.ump.edu.my/id/eprint/20659/1/Metformin%20-%20A%20Panacea%20Pharmaceutical%20Agent%20through%20convergence-fkksa-2017.pdf

id	ump-20659
recordtype	eprints
spelling	ump-206592018-03-01T05:25:31Z http://umpir.ump.edu.my/id/eprint/20659/ Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative Prabhakaran, Sonia Thirumal , Dhiviya Jolius, Gimbun Ranganathan, Balu TP Chemical technology Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation of diabetes. At the time of writing, metformin as an intervention is looked into for cardiovascular risks, polycystic ovary syndrome and breast cancer. Annual demand for Metformin is 23,000 Metric tons per annum. Nano Drug Delivery Systems (NDDS) has embarked into Metformin controlled and targeted delivery for breast cancer, pancreatic cancer and non-small cell lung cancer. Clinical estimation of the biological fluids by the FDA approved diagnostic laboratories use LC-MS/MS where blood samples estimate Metformin as an intact molecule easing the pressure of clinical trials result. Metformin was manufactured by a less known and low profile Aoron pharmaceutical, France not aware of the block buster drug hence the potential of technology development start-ups can neither be underwritten nor underestimated even when there is a very high rate (~90%) of failed biotech/biomed start-up ventures. The bloom of the French lilac (metformin) to blossom and flower for the cure of breast cancer by convergence revolution initiative with the integration of academia, hospital, technology business incubator, multinational corporation with the deliverance of a start-up company Informatics Publishing Limited 2017 Article PeerReviewed application/pdf en cc_by http://umpir.ump.edu.my/id/eprint/20659/1/Metformin%20-%20A%20Panacea%20Pharmaceutical%20Agent%20through%20convergence-fkksa-2017.pdf Prabhakaran, Sonia and Thirumal , Dhiviya and Jolius, Gimbun and Ranganathan, Balu (2017) Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative. Journal of Natural Remedies, 17 (3). pp. 69-79. ISSN 2320-3358 http://www.informaticsjournals.com/index.php/jnr/article/view/17938
repository_type	Digital Repository
institution_category	Local University
institution	Universiti Malaysia Pahang
building	UMP Institutional Repository
collection	Online Access
language	English
topic	TP Chemical technology
spellingShingle	TP Chemical technology Prabhakaran, Sonia Thirumal , Dhiviya Jolius, Gimbun Ranganathan, Balu Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
description	Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation of diabetes. At the time of writing, metformin as an intervention is looked into for cardiovascular risks, polycystic ovary syndrome and breast cancer. Annual demand for Metformin is 23,000 Metric tons per annum. Nano Drug Delivery Systems (NDDS) has embarked into Metformin controlled and targeted delivery for breast cancer, pancreatic cancer and non-small cell lung cancer. Clinical estimation of the biological fluids by the FDA approved diagnostic laboratories use LC-MS/MS where blood samples estimate Metformin as an intact molecule easing the pressure of clinical trials result. Metformin was manufactured by a less known and low profile Aoron pharmaceutical, France not aware of the block buster drug hence the potential of technology development start-ups can neither be underwritten nor underestimated even when there is a very high rate (~90%) of failed biotech/biomed start-up ventures. The bloom of the French lilac (metformin) to blossom and flower for the cure of breast cancer by convergence revolution initiative with the integration of academia, hospital, technology business incubator, multinational corporation with the deliverance of a start-up company
format	Article
author	Prabhakaran, Sonia Thirumal , Dhiviya Jolius, Gimbun Ranganathan, Balu
author_facet	Prabhakaran, Sonia Thirumal , Dhiviya Jolius, Gimbun Ranganathan, Balu
author_sort	Prabhakaran, Sonia
title	Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
title_short	Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
title_full	Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
title_fullStr	Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
title_full_unstemmed	Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
title_sort	metformin - a panacea pharmaceutical agent through convergence revolution initiative
publisher	Informatics Publishing Limited
publishDate	2017
url	http://umpir.ump.edu.my/id/eprint/20659/ http://umpir.ump.edu.my/id/eprint/20659/ http://umpir.ump.edu.my/id/eprint/20659/1/Metformin%20-%20A%20Panacea%20Pharmaceutical%20Agent%20through%20convergence-fkksa-2017.pdf
first_indexed	2023-09-18T22:29:55Z
last_indexed	2023-09-18T22:29:55Z
_version_	1777416217069355008

Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative

Similar Items